CD38 Assay Portfolio Service
Supported by in-house scientists and a first-in-class technical platform, Creative Biolabs is confident in providing an integrated solution for CD38 assay services to facilitate your project success.
Tumor Target CD38
CD38 is a 45 kDa single-chain type II transmembrane glycoprotein, with a short 20-AA N-terminal cytoplasmic tail and a long 256-aa extracellular domain. CD38 is expressed on several hematological malignancies and tumor-related immunosuppressive cells, including regulatory T cells, regulatory B cells, and bone marrow-derived suppressor cells.
CD38 possesses multiple functions, such as enzyme activity, adhesion effects, playing a vital role in normal cell functions and tumor growth. CD38 has important enzymatic functions, interacting with the substrate ligands NAD and NADP, which can be transformed into cADPR, ADPR and NAADP. As a receptor for ligand CD31 and hyaluronic acid, CD38 mediates cell proliferation, adhesion and T-cell activation.
Fig.1 Structural and functional characteristics of the human CD38 molecule. (Malavasi, 2011)
CD38 Targeted Therapies
Based on the high expression on plasma cell surfaces, therapies approaches targeting CD38 could provide more effective treatment options for multiple myeloma (MM) patients. During past decades, several novel CD38-targeting strategies have been developed, primarily for MM but also for other hematologic malignancies and solid tumors. In November 2015, daratumumab (Darzalex) became the first monoclonal antibody (mAb) targeting CD38 to receive FDA approval for MM patients. Notably, BM38, a dual-targeted CAR, has recently shown promise in a phase 1 study in relapsed/refractory disease.
Fig.2 CD38-targeted therapies approaches.
Our CD38 Assay Portfolio Services
Creative Biolabs’ scientists are dedicated to bringing together years of valuable experience to help our clients shorten the research journey. We are committed to developing tumor marker assay platforms, and providing high-quality CD38 assay portfolio services, and are dedicated to reducing the overall project development timeline for our clients.
We provide the following assays for our clients, which including but not limited to:
-
In vitro Assays:
-
CD38-targeted leads screening
-
Binding affinity test
-
Epitope mapping
-
Functional assay
-
In vivo assays:
-
Model construction
-
PK/PD study
For further details, please don't hesitate to contact us .
References
-
Malavasi, F.; et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011, 118(13): 3470-3478.
-
Jiao, Y.; et al. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. Expert opinion on investigational drugs. 2020, 29(11): 1295-308.
For Research Use Only | Not For Clinical Use
Download our brochure